Development of Biologics for Stroke

• Stem Cellular Therapy
• Targeting Gut Microbiota
• Therapeutic Antibodies
• Exosome-Based Therapy
• UCHL1-Based Therapy

Targeting stroke to develop stem cell therapies is a hot direction at present. Much data have shown that stem cell therapy is a potentially effective pathway for subacute and chronic stroke. Stem cell therapy treats stroke through two main pathways: cell differentiation and secretion of paracrine factors, Ace Therapeutics provides comprehensive preclinical research services, from screening for appropriate stem cell types to safety evaluation, to promote the development of your stem cell therapy for stroke.

Development of Stem Cell Therapy for Stroke

It has been shown that stem cell therapy has demonstrated potent therapeutic effects in stroke treatment not only in preclinical studies but also in clinical trials. Although other issues remain to be addressed, stem cell therapy is indeed an effective way to treat stroke. Ace Therapeutics offers comprehensive services to target the development of stem cell therapy for stroke treatment.

• For the development of stem cell therapies, we provide a cell bank of different types of stem cells, covering the stem cells needed for stem cell therapies that can be used to treat stroke.
• For stem cell transplantation pathways, we provide brain-targeted pathway screening protocols to ensure applicability to the needs of different studies based on the actual stroke situation.
• For the preclinical activity of stem cell therapies for stroke, we provide a comprehensive evaluation service to ensure that the therapies are effective.

Stroke Drug Development Targeting Gut Microbiota

Gut microbiota and their metabolites play an important role in stroke pathology. The gut microbiota can modulate the immune and nervous systems and thus the stroke onset process through bacterial molecules and metabolites. For example, it has been shown that the bacterial metabolite short-chain fatty acids contribute to post-stroke recovery. In view of this, Ace Therapeutics offers comprehensive services to develop stroke therapies targeting the gut microbiota. Our services cover research in fecal microbiota transplantation, bacterial formulation, and small molecule regulators for stroke therapy. With the latest technology and theory, we offer comprehensive services for your research on gut microbiota-based stroke therapies.

Development of Therapeutic Antibodies for Stroke

It is an effective treatment for stroke through antibody administration for passive immunotherapy. Many preclinical studies have demonstrated that the administration of therapeutic antibodies can reduce brain injury in animal models of stroke. However, the results of clinical trials have been less than satisfactory. Therefore, more effort and research are needed to refine therapeutic antibodies for stroke treatment. Ace Therapeutics offers comprehensive services to develop therapeutic antibodies for stroke. We have established antibody screening platforms for important targets in the stroke process. Different screening methods are used to efficiently obtain potentially active therapeutic antibodies.

Development of Exosome-Based Stroke Therapy

Exosomes are one of the major members of extracellular vesicles, which contain many biologically functional active molecules such as nucleic acids and proteins. Exosomes play an important role in regulating intercellular communication. Studies have shown that exosomes may be associated with neuroprotection, repair, and remodeling during stroke pathology. Therefore, the development of stroke therapies based on exosomes is a potential avenue for the treatment of stroke. Ace Therapeutics offers comprehensive services to develop stroke therapies based on exosomes.

Development of UCHL1-Based Stroke Therapy

UCHL1 is a neuron-specific protein whose activity is essential for improving the pathological process of stroke. Therefore, maintaining or restoring UCHL1 activity is a potential therapeutic approach for the treatment of stroke. Ace Therapeutics offers comprehensive services to develop stroke therapies targeting UCHL1.

• TAT-UCHL1 binding makes it easier for UCHL1 to enter neurons, which is an important way to restore UCHL1 activity in the brain.
• The C152 site of UCHL1 is a key binding site for active lipids. Mutations at this site are effective in reducing stroke damage to the gray and white matter of the brain.

We offer custom stem cell therapy development services for the treatment of stroke based on your experimental needs. If you would like to learn more about our services, please feel free to contact us.